Lv3
370 积分 2022-08-29 加入
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
2个月前
已完结
QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
4个月前
已完结
Aggregation of Adverse Event Terms for Signal Detection and Labeling in Clinical Trials
5个月前
已完结
Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
6个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
6个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
